Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; Romiplate/Nplate, a genetically recombinant protein for platelet production of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. Kyowa Kirin Co., Ltd. has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.

Kyowa Kirin Co., Ltd.

Marifarm d.o.o. is a pharmaceutical company that provides high-quality contract services and ensures effective communication with contract manufacturing partners at all work stages.

Marifarm

Kyowa Kirin is a global specialty pharmaceutical company that applies state-of-the-art biotechnologies to discover and deliver novel medicines. We work on some of the hardest to treat diseases where need is high, and potential for life-changing impact is possible.

The North America organization includes three offices in New Jersey and California that focus on drug discovery, product development, and commercialization. Together, we work as a collaborative team to understand clinical needs and advance innovations that have a profound impact on patient lives. 

Our growth in North America relies on entrepreneurial team players who are willing to share their expertise and ideas in an environment that prioritizes innovation, diversity, integrity and “wa.” Each person plays a significant role in shaping the work we do and the results we deliver.

Kyowa Kirin, Inc.- U.S.

Our company is excited to join the NC biopharma community, and looks forward to sharing more plans soon.  https://bit.ly/49MSwrq

Did you know that there are over 6,000 distinct rare conditions, currently affecting about 300 million people worldwide and it takes approximately five years on average for rare disease patients to get a diagnosis?

At Kyowa Kirin, we engage with and listen closely to our external environment, so as we approach #RareDiseaseDay, we wanted to shine a light on the stories of those affected by rare diseases. 

#KKIMakingPeopleSmile #RareDiseaseMonth

Doug Grant, our General Manager for Canada, reflects on what the timely access to care means for those patients living with #raredisease.  

#RareDiseaseDay #ShowYourStripes

Kyowa Kirin is constantly seeking ways to meet the needs of those we serve, no matter where they are in the world. Hear from our global Kyowa Kirin leaders about how our Commitment to Life mission statement is rooted within our organization and helps us deliver on our promise to bring more smiles to those living with a #raredisease. 

#KKIMakingPeopleSmile

Everyone should have a chance to live life to the fullest. This #RareDiseaseDay, Kyowa Kirin joins the rare community in advocating for equitable access to timely diagnosis, treatment, and care for people living with rare diseases.

#RareDiseaseMonth #ShareYourRare #ShowYourStripes #ShowYourColours

Kyowa Kirin is proud to sponsor #RareDiseaseDay through National Organization for Rare Disorders. Together we seek to raise awareness of the challenges millions of rare disease patients face.

#RareDiseaseMonth #ShareYourRare #ShowYourColours

Had a wonderful time with Kyowa Kirin, Inc.- U.S. colleagues at last night’s BioNJ Annual Dinner, celebrating many accomplished and dedicated leaders working on behalf of patients. Congrats to my old colleague, Mark Peters  II, for being honored - and continuing to inspire so many others!
And thanks Debbie Hart 👏👏


Tara D'Orsi Greg Palko RPh, MBA Kevin Lynch

This International Day of Women and Girls in Science we celebrate the innovation and fresh perspectives that women and girls bring to scientific discovery.

Listen as our own Rachel Soloff, Ph.D., Executive Director of Research reflects on what drove her to choose a #STEM career. 

Today and every day, we welcome people to join us who share our commitment to making a profound impact on patients’ lives: https://bit.ly/49bVjL4

#WomenInScience #IDWGS

Throughout #RareDiseaseMonth, and every day of the year, we remain steadfast in our commitment to the #raredisease community. We are constantly seeking ways to meet the needs of the people we serve, no matter where they are in the world, and will work endlessly to develop new, innovative technologies to help bring smiles to those living with a rare disease.

#KKIMakingPeopleSmile #ProfoundImpact

Kyowa Kirin Co., Ltd. 
Kyowa Kirin Asia Pacific 
Kyowa Kirin International plc.

Metric
Company Name	Kyowa Kirin Co., Ltd.	Marifarm
Symbol	4.15K
MSH ID	COM:KYOWAKIRIN	SI:MARIFARM
Market	STOCKS	PRIVATE
Sector	Healthcare	Healthcare & Health Services
Industry	Drug Manufacturers - General	Pharmaceuticals
Country	JP	SI
Stage
Employee Count	5.97K
Website	kyowakirin.com	marifarm.si
LinkedIn	kyowa-kirin-inc.--u.s.
Founders

Metric
Market Cap	11.07B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	2.95B
Revenue (LTM)
Revenue (NTM)
Gross Profit	2.14B
EBITDA	779.90M
Operating Income	639.20M
Net Income	541.47M
EPS	1.01
Diluted EPS	1.01
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.74
Operating Profit Margin	0.25
EBITDA Margin	0.26
Net Profit Margin	0.20
Return on Equity	0.12
Return on Assets	0.09
Return on Capital Employed	0.13

4151

COM:KYOWAKIRIN

Kyowa Kirin Co., Ltd.

Last Close

2,523.00

25/11 06:45

Market Cap

1.66T

Beta: -

Volume Today

2.98M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	21.47
P/B Ratio	1.53
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	3.76
EV Multiple	16.23

Metric
Days Sales Outstanding	98.59
Days Payables Outstanding	327.25
Days Inventory Outstanding	228.53
Operating Cycle	326.81
Cash Conversion Cycle	29.05
Asset Turnover	0.44

Metric
Operating Cash Flow	770.65M
Free Cash Flow	551.55M
Cash Flow to Debt	14.20
Operating Cash Flow/Sales	0.26
Free Cash Flow Yield	0.05

Metric
Cash & Equivalents	2.69B
Accounts Receivable	-19.55M
Inventory	475.94M
Goodwill	936.71M
Debt to Capitalization	0.03
Debt to Assets
Current Ratio	4.38
Quick Ratio	3.93

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue	0.17
SG&A to Revenue	0.40